Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Mother and child, waiting at a health centre © Credit: Dominic Chavez World Bank

Similar stories

Landmark DeTACT project holds final Investigators’ meeting

On 6-7 May in Zanzibar, Tanzania, the final investigators’ meeting of the Development of Triple Artemisinin-based Combination Therapies (DeTACT) project brought together 35 investigators from participating institutions in Bangladesh, Cambodia, Guinea, Nigeria, Niger, Tanzania, The Gambia, Rwanda, Singapore, and MORU, along with key partners from Fosun Pharma, Medicines for Malaria Venture (MMV), the WHO Global Malaria Programme, and the UK Foreign, Commonwealth and Development Office (FCDO), which funded the project over the past seven years.